LFF-571

Summary

LFF-571 is an investigational, orally administered semisynthetic thiopeptide antibiotic derived from the streptogramin/depsipeptide family. It is being explored as a narrow‑spectrum agent for the treatment of Clostridioides difficile infection (CDI), including recurrent disease, where current therapies show high relapse rates.

Mechanism of Action

LFF-571 is reported to inhibit bacterial protein synthesis. While the exact molecular target is not detailed in the cited literature, thiopeptide antibiotics typically bind to the bacterial ribosome, interfering with the translation process and halting growth of C. difficile cells.

What the Research Shows

The three cited reviews list LFF-571 among agents that have reached at least Phase 2 clinical development for CDI. It is highlighted for its novel mechanism—blocking protein synthesis—and oral delivery, which could differentiate it from existing intravenously administered drugs. No primary clinical trial data are presented; the discussion is limited to expert opinion and overview of the development pipeline. Consequently, the evidence base consists mainly of early‑stage trial inclusion and theoretical advantages rather than published efficacy or safety outcomes.

Reported Benefits

Potential benefits include oral administration, a novel mechanism distinct from vancomycin or fidaxomicin, and a narrow antimicrobial spectrum that may spare the normal gut flora. These attributes could translate into lower recurrence rates for CDI, but such effects remain speculative pending trial results.

Limitations of the Evidence

Current knowledge is confined to early‑stage development and expert commentary; no peer‑reviewed efficacy or safety data have been published. The absence of clinical trial outcomes means the true therapeutic advantage, optimal dosing, and resistance profile are unknown. Comparisons with established CDI treatments are therefore unavailable.

Safety Considerations

The abstracts do not provide any safety or adverse‑event information for LFF-571. As an investigational product, its tolerability and potential side‑effects have not been characterized in the public literature, and safety can only be inferred from the general class of thiopeptide antibiotics, which may have limited systemic absorption. Caution is warranted until formal trial data emerge.

How It Is Administered

LFF-571 is being formulated for oral delivery. Details of dosage form, strength, or regimen have not been disclosed in the cited sources; the compound remains investigational and is not approved for clinical use.

Routes of Administration

Goals & Uses

• Gram-positive bacterial infection treatmentAntimicrobialLow
• Reduction of CDI recurrenceAntimicrobial / GastrointestinalLow
• Treatment of Clostridioides difficile infectionAntimicrobialModerate

Contraindications

• Hypersensitivity to thiopeptide antibiotics or GE2270A derivativesAllergyHigh

Adverse Effects

• HeadacheNeurologicUncommonPain in the head or upper neck
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• VomitingGastrointestinalCommonForceful expulsion of stomach contents
• Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
• Abdominal painGastrointestinalUncommonPain or discomfort in the abdomen

Drug Interactions

• CYP3A4 substratesLow

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant womenReproductiveRelative
• Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionInvestigationalNo marketing authorization granted; limited EU trial data publicly available.
• United StatesInvestigationalInvestigated under IND for CDI; Phase II completed (NCT01232595); no NDA filed as of available data.

Not approved by any regulatory authority. Evaluated in Phase II clinical trials (NCT01232595) for Clostridioides difficile infection. Novartis has not advanced the compound to Phase III registration trials.

Evidence & Sources

• Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection
  Journal ArticleModerateTran MN, Kullar R, Goldstein EJC2019-01-01T00:00:00.000000Z
• Therapy of Clostridium difficile infection: perspectives on a changing paradigm
  Journal ArticleModerateTran MC, Claros MC, Goldstein EJ2013-01-01T00:00:00.000000Z
• Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
  Journal ArticleModerateKullar R, Tran MN, Goldstein EJC2020-01-01T00:00:00.000000Z

Frequently Asked Questions